Desmoplastic small round cell tumour
Prepared with OnCo (onco.cc/prep/desmoplastic-small-round-cell-tumour/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
8 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example EWSR1-WT1 fusion; WT1 C-terminus immunohistochemistry, Polyphenotypic staining, Peritoneal cancer index and completeness of cytoreduction, PDGFR-alpha and VEGF expression), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (all cases), which of the standard options do you recommend and why?
- 6.Am I a candidate for Vincristine, Doxorubicin, Cyclophosphamide or related drugs, and what side effects should I expect?
- 7.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 8.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Tests and results to bring
Biomarker results to ask for: EWSR1-WT1 fusion (FISH or RT-PCR); WT1 C-terminus immunohistochemistry, Polyphenotypic staining (cytokeratin, desmin, neural markers), Peritoneal cancer index and completeness of cytoreduction, PDGFR-alpha and VEGF expression (targets).
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- All cases: Ewing-type multi-agent chemotherapy, complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy, radiotherapy in some centres; pazopanib, sunitinib or mTOR inhibitors on relapse; trials recommended. (Sarcomas (soft tissue, bone, GIST), Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, Etoposide, HIPEC / PIPAC (intraperitoneal chemotherapy), Pazopanib, Sunitinib)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.